CAR T-Cell Therapy Market Set for Exponential Growth to USD 129.45 Billion by 2034

The global CAR T-cell therapy market was worth USD 11.11 billion in 2024 and is expected to reach around USD 129.45 billion by 2034, with a noteworthy CAGR of 27.83% from 2025 to 2034. The growing demand for therapeutics for rare diseases is driving the CAR T-cell therapy market growth.

Utilizing immune cells called T cells that have been genetically modified in a lab to improve their ability to recognize and eliminate cancer cells, CAR T-cell therapy is a form of cancer immunotherapy treatment. Multiple hematological malignancies, including lymphoma and leukemia, can be treated with CAR T treatment, according to FDA approval.

The growing interest of stakeholders in this field is due to the rising number of strategic alliances formed for the development of CAR T-cell therapies in recent years. While the approval process for CAR-T therapies is expedited through various grants, the high cost of treatment options remains a major challenge for the adoption of CAR T cell therapy.

• Over the past eight years, approximately 1,000 clinical trials related to CART-cell therapies have been registered, showing significant research activity in this area. Of these trials, nearly 60% are currently recruiting patients to assess drugs for different types of oncological, non-oncological, and other disorders.

Get Sample: https://www.cervicornconsulting.com/sample/2346

1. Personalized Treatment- The ability that CAR T-cell therapies carry to be customized according to the patients’ requirements are being explored, especially through the oncology sector’s medicine landscape.
2. Investments & Business Activities- The CAR T-cell therapy market is observed to witness a surge in the years with rising mergers and acquisitions in the industry. Major pharma companies are seen raising funds and venture capital for therapy development that signals a potential for the industry.
3. Clinical Advancements- In order to emphasize over improved safety profiles and combination therapies, ongoing research and development activities are addressing various forms of CAR T-cell therapies.

The market is highly competitive due to the presence of several international companies. The most important factors that are affecting the competitive nature are the quick adoption of advanced technology for improved healthcare. Moreover, players are acquiring, partnering, and collaborating with other firms to gain a higher market share.

• In July 2024, in an effort to improve the treatment of multiple myeloma, the Multiple Myeloma Research Foundation (MMRF) invested USD 1 million through its Myeloma Investment Fund in Dynamic Cell Therapies' (DCT) cutting-edge CAR T-cell technology.
• In March 2023, to expand its portfolio of Next Generation CAR T-Cell treatments, CARGO Therapeutics secured USD 200 million in oversubscribed, oversized aeries fundraising.
• In February 2024, a major partnership between BioNTech and Autolus for CAR-T cell therapy was announced with the goal of expanding late-stage studies and advancing the pipeline. Autolus receives a USD 200 million investment from BioNTech.

When other cancer therapies are failing, CAR T-cell therapy can be incredibly successful in treating particular cancer types. CAR T-cell therapy is a kind of cancer immunotherapy treatment that makes use of T cells, which are immune cells that have undergone genetic alteration in a lab to improve their ability to identify and eliminate cancer cells.

• WHO estimates that in 2022, there will be 20 million new cases of cancer and 7 million cancer-related deaths. It was projected that 53.5 million people would still be alive five years after receiving a cancer diagnosis.
• In February 2024, 2 exclusive option and licensing agreements were announced today by AbbVie and Umoja Biopharma (Umoja), an early-stage clinical biotechnology firm, to develop several in-situ produced CART-cell treatments.
• In January 2024, Kite Pharma received FDA's approval of their advancement in manufacturing process for axicabtageneciloleucel (Yescarta®), significantly eliminating the median turnaround time.

North America dominated the CAR T-cell therapy market in 2023. Due to rising rates of diagnosis and treatment for hematologic cancer as well as its increasing incidence, the region is expected to continue to lead the market over the projection period. Furthermore, in the major nations in the area, the availability of sufficient compensation for inpatient hospital stays promotes the uptake of cutting-edge medical care.

• In September 2022, CARsgenTherapeutics Co., Ltd. presented the results of the phase 2 clinical study of zevorcabtageneautoleucel (CT 053) in North America. The purpose of the trial was to evaluate the treatment's safety and effectiveness in treating patients with relapsed or resistant multiple myeloma in North America.

Asia Pacific is estimated to grow fastest during the forecast period. Cancer is quickly growing from being a minor public health concern to a major one in India. The first CAR-T treatment produced in India, NexCAR19, was developed through a collaboration between academics and businesses. In the globe, NexCAR19 is the most economical CAR-T treatment.

• India had around 6 million new cancer diagnoses in 2023, up from roughly 980,000 in 2010, according to the latest current projections. It is predicted that 800,000 people die from cancer each year; this figure is projected to rise significantly over the next several decades.

Improved treatment options are necessary for conditions such as cancer, infectious diseases, and non-communicable diseases. The global population exhibits a wide range of illness profiles, with developing countries having the most diverse disease profiles.

• Gilead Sciences, Inc.
• Novartis International AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• Kite Pharma, Inc. (a Gilead company)
• Juno Therapeutics, Inc. (a Bristol-Myers Squibb company)
• Bluebird Bio, Inc.
• TCR2 Therapeutics Inc.
• Legend Biotech Corporation
• Celyad Oncology SA
• CARsgen Therapeutics Holdings Limited
• AbbVie Inc.
• Sorrento Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Autolus Therapeutics plc

The success of ongoing trials and future research in the field of CAR T-cell will directly impact the future of the CAR T-cell therapy market. T cell therapies are often labor and cost intensive due to their complex nature and the pricey reagents required. Innovative methods and techniques to create more potent CAR-T cells with enhanced anti-tumor activity and reduced toxicity are required to overcome these major obstacles.

• In March 2023, Massachusetts General Hospital designed a novel CAR-T cell approach to treat glioblastoma. Two existing strategies, CAR-T and bispecific antibodies were combined by researchers to develop this effective treatment.
• In July 2024, Nature Medicine published an article discussing CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma. The study funded by Celgene, a Bristol-Myers Squibb company showed immense success during clinical testing.

Cytokine release syndrome is a serious side effect associated with CAR T cell treatment (CRS). Cytokines are molecules that CAR T cells may produce that trigger an immune system response.

• By drug type, the axicabtageneciloleucelsegment holds a substantial share of the market due to it higher success rates.
• By indication, the lymphoma segment leads the market due the efforts invested in research for treatments of different forms of lymphomas.
• By end-use, the hospital segment dominated the market in 2023 as they are equipped to deal with CAR T-cell treatments related complications.
• By end-use, the cancer treatment centers segment is estimated to grow at the fastest rate in the market due to the prevalence of oncological conditions and associated death rates.

• In May 2024, Astellas Pharma Inc. and Poseida Therapeutics, Inc. announced that Xyphos Biosciences, Inc. and Poseida have joined forces in a research and licensing agreement to combine their respective cutting-edge cell therapy platforms to develop new convertibleCAR® initiatives.
• In December 2023, at its facility in Delhi-NCR, Max Healthcare announced the introduction of chimeric antigen receptor (CAR)-T cell treatment.

Segments Covered in the Report

By Product 

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Carvykti (ciltacabtagene autoleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Others

By Disease Indication 

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

By End-Use 

• Hospitals
• Cancer Treatment Centers

By region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Buy Report: https://www.cervicornconsulting.com/buy-now/2346